miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death

MicroRNAs (miRNA) are noncoding RNAs that regulate multiple cellular processes, including proliferation and apoptosis. We used microarray technology to identify miRNAs that were upregulated by non-small cell lung cancer (NSCLC) A549 cells in response to cisplatin (CDDP). The corresponding synthetic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 2010-03, Vol.70 (5), p.1793-1803
Hauptverfasser: GALLUZZI, Lorenzo, MORSELLI, Eugenia, RIPOCHE, Hugues, LAZAR, Vladimir, HAREL-BELLAN, Annick, DESSEN, Philippe, BARILLOT, Emmanuel, KROEMER, Guido, VITALE, Ilio, KEPP, Oliver, SENOVILLA, Laura, CRIOLLO, Alfredo, SERVANT, Nicolas, PACCARD, Caroline, HUPE, Philippe, ROBERT, Thomas
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1803
container_issue 5
container_start_page 1793
container_title Cancer research (Chicago, Ill.)
container_volume 70
creator GALLUZZI, Lorenzo
MORSELLI, Eugenia
RIPOCHE, Hugues
LAZAR, Vladimir
HAREL-BELLAN, Annick
DESSEN, Philippe
BARILLOT, Emmanuel
KROEMER, Guido
VITALE, Ilio
KEPP, Oliver
SENOVILLA, Laura
CRIOLLO, Alfredo
SERVANT, Nicolas
PACCARD, Caroline
HUPE, Philippe
ROBERT, Thomas
description MicroRNAs (miRNA) are noncoding RNAs that regulate multiple cellular processes, including proliferation and apoptosis. We used microarray technology to identify miRNAs that were upregulated by non-small cell lung cancer (NSCLC) A549 cells in response to cisplatin (CDDP). The corresponding synthetic miRNA precursors (pre-miRNAs) per se were not lethal when transfected into A549 cells yet affected cell death induction by CDDP, C2-ceramide, cadmium, etoposide, and mitoxantrone in an inducer-specific fashion. Whereas synthetic miRNA inhibitors (anti-miRNAs) targeting miR-181a and miR-630 failed to modulate the response of A549 to CDDP, pre-miR-181a and pre-miR-630 enhanced and reduced CDDP-triggered cell death, respectively. Pre-miR-181a and pre-miR-630 consistently modulated mitochondrial/postmitochondrial steps of the intrinsic pathway of apoptosis, including Bax oligomerization, mitochondrial transmembrane potential dissipation, and the proteolytic maturation of caspase-9 and caspase-3. In addition, pre-miR-630 blocked early manifestations of the DNA damage response, including the phosphorylation of the ataxia-telangiectasia mutated (ATM) kinase and of two ATM substrates, histone H2AX and p53. Pharmacologic and genetic inhibition of p53 corroborated the hypothesis that pre-miR-630 (but not pre-miR-181a) blocks the upstream signaling pathways that are ignited by DNA damage and converge on p53 activation. Pre-miR-630 arrested A549 cells in the G0-G1 phase of the cell cycle, correlating with increased levels of the cell cycle inhibitor p27(Kip1) as well as with reduced proliferation rates and resulting in greatly diminished sensitivity of A549 cells to the late S-G2-M cell cycle arrest mediated by CDDP. Altogether, these results identify miR-181a and miR-630 as novel modulators of the CDDP response in NSCLC.
doi_str_mv 10.1158/0008-5472.can-09-3112
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733690564</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733690564</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-8efd5290870b8785fbbde875b77b30c76fa97bb69ada84f9ae4a88a2143e387f3</originalsourceid><addsrcrecordid>eNpFkE1PwzAMhiMEYmPwE0C9IE6BpEma5DiVr0kTSBOcIydNoKjtRrMe-Pek2hgn29Lz2taD0CUlt5QKdUcIUVhwmd866DDRmFGaH6EpFUxhybk4RtMDM0FnMX6lUVAiTtEkJ5QLKvIpmrf1ClNFIYOuysahYCRb-Y-hga3PyjpuUlN3eNFVg_NVVkLnfJ-Vvmmyew_bz3N0EqCJ_mJfZ-j98eGtfMbL16dFOV9il05tsfKhErkmShKrpBLB2sorKayUlhEniwBaWltoqEDxoMFzUApyyplnSgY2Qze7vZt-_T34uDVtHV16Azq_HqKRjBWaiIInUuxI169j7H0wm75uof8xlJhRnhnFmFGMKecvhmgzyku5q_2Fwba-OqT-bCXgeg9AdNCEPrmo4z-Xc1UQqdkvSMN1AQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733690564</pqid></control><display><type>article</type><title>miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>GALLUZZI, Lorenzo ; MORSELLI, Eugenia ; RIPOCHE, Hugues ; LAZAR, Vladimir ; HAREL-BELLAN, Annick ; DESSEN, Philippe ; BARILLOT, Emmanuel ; KROEMER, Guido ; VITALE, Ilio ; KEPP, Oliver ; SENOVILLA, Laura ; CRIOLLO, Alfredo ; SERVANT, Nicolas ; PACCARD, Caroline ; HUPE, Philippe ; ROBERT, Thomas</creator><creatorcontrib>GALLUZZI, Lorenzo ; MORSELLI, Eugenia ; RIPOCHE, Hugues ; LAZAR, Vladimir ; HAREL-BELLAN, Annick ; DESSEN, Philippe ; BARILLOT, Emmanuel ; KROEMER, Guido ; VITALE, Ilio ; KEPP, Oliver ; SENOVILLA, Laura ; CRIOLLO, Alfredo ; SERVANT, Nicolas ; PACCARD, Caroline ; HUPE, Philippe ; ROBERT, Thomas</creatorcontrib><description>MicroRNAs (miRNA) are noncoding RNAs that regulate multiple cellular processes, including proliferation and apoptosis. We used microarray technology to identify miRNAs that were upregulated by non-small cell lung cancer (NSCLC) A549 cells in response to cisplatin (CDDP). The corresponding synthetic miRNA precursors (pre-miRNAs) per se were not lethal when transfected into A549 cells yet affected cell death induction by CDDP, C2-ceramide, cadmium, etoposide, and mitoxantrone in an inducer-specific fashion. Whereas synthetic miRNA inhibitors (anti-miRNAs) targeting miR-181a and miR-630 failed to modulate the response of A549 to CDDP, pre-miR-181a and pre-miR-630 enhanced and reduced CDDP-triggered cell death, respectively. Pre-miR-181a and pre-miR-630 consistently modulated mitochondrial/postmitochondrial steps of the intrinsic pathway of apoptosis, including Bax oligomerization, mitochondrial transmembrane potential dissipation, and the proteolytic maturation of caspase-9 and caspase-3. In addition, pre-miR-630 blocked early manifestations of the DNA damage response, including the phosphorylation of the ataxia-telangiectasia mutated (ATM) kinase and of two ATM substrates, histone H2AX and p53. Pharmacologic and genetic inhibition of p53 corroborated the hypothesis that pre-miR-630 (but not pre-miR-181a) blocks the upstream signaling pathways that are ignited by DNA damage and converge on p53 activation. Pre-miR-630 arrested A549 cells in the G0-G1 phase of the cell cycle, correlating with increased levels of the cell cycle inhibitor p27(Kip1) as well as with reduced proliferation rates and resulting in greatly diminished sensitivity of A549 cells to the late S-G2-M cell cycle arrest mediated by CDDP. Altogether, these results identify miR-181a and miR-630 as novel modulators of the CDDP response in NSCLC.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>DOI: 10.1158/0008-5472.can-09-3112</identifier><identifier>PMID: 20145152</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Antineoplastic agents ; Antineoplastic Agents - pharmacology ; Apoptosis - drug effects ; Apoptosis - genetics ; bcl-2-Associated X Protein - metabolism ; Biological and medical sciences ; Cadmium Chloride - pharmacology ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - metabolism ; Carcinoma, Non-Small-Cell Lung - pathology ; Caspases - metabolism ; Cell Cycle - drug effects ; Cell Cycle - genetics ; Cell Line, Tumor ; Cisplatin - pharmacology ; DNA Damage ; HeLa Cells ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - metabolism ; Lung Neoplasms - pathology ; Medical sciences ; MicroRNAs - genetics ; MicroRNAs - metabolism ; MicroRNAs - physiology ; Oligonucleotide Array Sequence Analysis - methods ; Pharmacology. Drug treatments ; Phosphorylation ; Sphingosine - analogs &amp; derivatives ; Sphingosine - pharmacology ; Tumor Suppressor Protein p53 - genetics ; Tumor Suppressor Protein p53 - metabolism ; Tumors ; Up-Regulation - drug effects</subject><ispartof>Cancer research (Chicago, Ill.), 2010-03, Vol.70 (5), p.1793-1803</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-8efd5290870b8785fbbde875b77b30c76fa97bb69ada84f9ae4a88a2143e387f3</citedby><cites>FETCH-LOGICAL-c451t-8efd5290870b8785fbbde875b77b30c76fa97bb69ada84f9ae4a88a2143e387f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22486079$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20145152$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GALLUZZI, Lorenzo</creatorcontrib><creatorcontrib>MORSELLI, Eugenia</creatorcontrib><creatorcontrib>RIPOCHE, Hugues</creatorcontrib><creatorcontrib>LAZAR, Vladimir</creatorcontrib><creatorcontrib>HAREL-BELLAN, Annick</creatorcontrib><creatorcontrib>DESSEN, Philippe</creatorcontrib><creatorcontrib>BARILLOT, Emmanuel</creatorcontrib><creatorcontrib>KROEMER, Guido</creatorcontrib><creatorcontrib>VITALE, Ilio</creatorcontrib><creatorcontrib>KEPP, Oliver</creatorcontrib><creatorcontrib>SENOVILLA, Laura</creatorcontrib><creatorcontrib>CRIOLLO, Alfredo</creatorcontrib><creatorcontrib>SERVANT, Nicolas</creatorcontrib><creatorcontrib>PACCARD, Caroline</creatorcontrib><creatorcontrib>HUPE, Philippe</creatorcontrib><creatorcontrib>ROBERT, Thomas</creatorcontrib><title>miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>MicroRNAs (miRNA) are noncoding RNAs that regulate multiple cellular processes, including proliferation and apoptosis. We used microarray technology to identify miRNAs that were upregulated by non-small cell lung cancer (NSCLC) A549 cells in response to cisplatin (CDDP). The corresponding synthetic miRNA precursors (pre-miRNAs) per se were not lethal when transfected into A549 cells yet affected cell death induction by CDDP, C2-ceramide, cadmium, etoposide, and mitoxantrone in an inducer-specific fashion. Whereas synthetic miRNA inhibitors (anti-miRNAs) targeting miR-181a and miR-630 failed to modulate the response of A549 to CDDP, pre-miR-181a and pre-miR-630 enhanced and reduced CDDP-triggered cell death, respectively. Pre-miR-181a and pre-miR-630 consistently modulated mitochondrial/postmitochondrial steps of the intrinsic pathway of apoptosis, including Bax oligomerization, mitochondrial transmembrane potential dissipation, and the proteolytic maturation of caspase-9 and caspase-3. In addition, pre-miR-630 blocked early manifestations of the DNA damage response, including the phosphorylation of the ataxia-telangiectasia mutated (ATM) kinase and of two ATM substrates, histone H2AX and p53. Pharmacologic and genetic inhibition of p53 corroborated the hypothesis that pre-miR-630 (but not pre-miR-181a) blocks the upstream signaling pathways that are ignited by DNA damage and converge on p53 activation. Pre-miR-630 arrested A549 cells in the G0-G1 phase of the cell cycle, correlating with increased levels of the cell cycle inhibitor p27(Kip1) as well as with reduced proliferation rates and resulting in greatly diminished sensitivity of A549 cells to the late S-G2-M cell cycle arrest mediated by CDDP. Altogether, these results identify miR-181a and miR-630 as novel modulators of the CDDP response in NSCLC.</description><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis - drug effects</subject><subject>Apoptosis - genetics</subject><subject>bcl-2-Associated X Protein - metabolism</subject><subject>Biological and medical sciences</subject><subject>Cadmium Chloride - pharmacology</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - metabolism</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Caspases - metabolism</subject><subject>Cell Cycle - drug effects</subject><subject>Cell Cycle - genetics</subject><subject>Cell Line, Tumor</subject><subject>Cisplatin - pharmacology</subject><subject>DNA Damage</subject><subject>HeLa Cells</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - metabolism</subject><subject>Lung Neoplasms - pathology</subject><subject>Medical sciences</subject><subject>MicroRNAs - genetics</subject><subject>MicroRNAs - metabolism</subject><subject>MicroRNAs - physiology</subject><subject>Oligonucleotide Array Sequence Analysis - methods</subject><subject>Pharmacology. Drug treatments</subject><subject>Phosphorylation</subject><subject>Sphingosine - analogs &amp; derivatives</subject><subject>Sphingosine - pharmacology</subject><subject>Tumor Suppressor Protein p53 - genetics</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><subject>Tumors</subject><subject>Up-Regulation - drug effects</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1PwzAMhiMEYmPwE0C9IE6BpEma5DiVr0kTSBOcIydNoKjtRrMe-Pek2hgn29Lz2taD0CUlt5QKdUcIUVhwmd866DDRmFGaH6EpFUxhybk4RtMDM0FnMX6lUVAiTtEkJ5QLKvIpmrf1ClNFIYOuysahYCRb-Y-hga3PyjpuUlN3eNFVg_NVVkLnfJ-Vvmmyew_bz3N0EqCJ_mJfZ-j98eGtfMbL16dFOV9il05tsfKhErkmShKrpBLB2sorKayUlhEniwBaWltoqEDxoMFzUApyyplnSgY2Qze7vZt-_T34uDVtHV16Azq_HqKRjBWaiIInUuxI169j7H0wm75uof8xlJhRnhnFmFGMKecvhmgzyku5q_2Fwba-OqT-bCXgeg9AdNCEPrmo4z-Xc1UQqdkvSMN1AQ</recordid><startdate>20100301</startdate><enddate>20100301</enddate><creator>GALLUZZI, Lorenzo</creator><creator>MORSELLI, Eugenia</creator><creator>RIPOCHE, Hugues</creator><creator>LAZAR, Vladimir</creator><creator>HAREL-BELLAN, Annick</creator><creator>DESSEN, Philippe</creator><creator>BARILLOT, Emmanuel</creator><creator>KROEMER, Guido</creator><creator>VITALE, Ilio</creator><creator>KEPP, Oliver</creator><creator>SENOVILLA, Laura</creator><creator>CRIOLLO, Alfredo</creator><creator>SERVANT, Nicolas</creator><creator>PACCARD, Caroline</creator><creator>HUPE, Philippe</creator><creator>ROBERT, Thomas</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100301</creationdate><title>miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death</title><author>GALLUZZI, Lorenzo ; MORSELLI, Eugenia ; RIPOCHE, Hugues ; LAZAR, Vladimir ; HAREL-BELLAN, Annick ; DESSEN, Philippe ; BARILLOT, Emmanuel ; KROEMER, Guido ; VITALE, Ilio ; KEPP, Oliver ; SENOVILLA, Laura ; CRIOLLO, Alfredo ; SERVANT, Nicolas ; PACCARD, Caroline ; HUPE, Philippe ; ROBERT, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-8efd5290870b8785fbbde875b77b30c76fa97bb69ada84f9ae4a88a2143e387f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis - drug effects</topic><topic>Apoptosis - genetics</topic><topic>bcl-2-Associated X Protein - metabolism</topic><topic>Biological and medical sciences</topic><topic>Cadmium Chloride - pharmacology</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - metabolism</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Caspases - metabolism</topic><topic>Cell Cycle - drug effects</topic><topic>Cell Cycle - genetics</topic><topic>Cell Line, Tumor</topic><topic>Cisplatin - pharmacology</topic><topic>DNA Damage</topic><topic>HeLa Cells</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - metabolism</topic><topic>Lung Neoplasms - pathology</topic><topic>Medical sciences</topic><topic>MicroRNAs - genetics</topic><topic>MicroRNAs - metabolism</topic><topic>MicroRNAs - physiology</topic><topic>Oligonucleotide Array Sequence Analysis - methods</topic><topic>Pharmacology. Drug treatments</topic><topic>Phosphorylation</topic><topic>Sphingosine - analogs &amp; derivatives</topic><topic>Sphingosine - pharmacology</topic><topic>Tumor Suppressor Protein p53 - genetics</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><topic>Tumors</topic><topic>Up-Regulation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GALLUZZI, Lorenzo</creatorcontrib><creatorcontrib>MORSELLI, Eugenia</creatorcontrib><creatorcontrib>RIPOCHE, Hugues</creatorcontrib><creatorcontrib>LAZAR, Vladimir</creatorcontrib><creatorcontrib>HAREL-BELLAN, Annick</creatorcontrib><creatorcontrib>DESSEN, Philippe</creatorcontrib><creatorcontrib>BARILLOT, Emmanuel</creatorcontrib><creatorcontrib>KROEMER, Guido</creatorcontrib><creatorcontrib>VITALE, Ilio</creatorcontrib><creatorcontrib>KEPP, Oliver</creatorcontrib><creatorcontrib>SENOVILLA, Laura</creatorcontrib><creatorcontrib>CRIOLLO, Alfredo</creatorcontrib><creatorcontrib>SERVANT, Nicolas</creatorcontrib><creatorcontrib>PACCARD, Caroline</creatorcontrib><creatorcontrib>HUPE, Philippe</creatorcontrib><creatorcontrib>ROBERT, Thomas</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GALLUZZI, Lorenzo</au><au>MORSELLI, Eugenia</au><au>RIPOCHE, Hugues</au><au>LAZAR, Vladimir</au><au>HAREL-BELLAN, Annick</au><au>DESSEN, Philippe</au><au>BARILLOT, Emmanuel</au><au>KROEMER, Guido</au><au>VITALE, Ilio</au><au>KEPP, Oliver</au><au>SENOVILLA, Laura</au><au>CRIOLLO, Alfredo</au><au>SERVANT, Nicolas</au><au>PACCARD, Caroline</au><au>HUPE, Philippe</au><au>ROBERT, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>2010-03-01</date><risdate>2010</risdate><volume>70</volume><issue>5</issue><spage>1793</spage><epage>1803</epage><pages>1793-1803</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>MicroRNAs (miRNA) are noncoding RNAs that regulate multiple cellular processes, including proliferation and apoptosis. We used microarray technology to identify miRNAs that were upregulated by non-small cell lung cancer (NSCLC) A549 cells in response to cisplatin (CDDP). The corresponding synthetic miRNA precursors (pre-miRNAs) per se were not lethal when transfected into A549 cells yet affected cell death induction by CDDP, C2-ceramide, cadmium, etoposide, and mitoxantrone in an inducer-specific fashion. Whereas synthetic miRNA inhibitors (anti-miRNAs) targeting miR-181a and miR-630 failed to modulate the response of A549 to CDDP, pre-miR-181a and pre-miR-630 enhanced and reduced CDDP-triggered cell death, respectively. Pre-miR-181a and pre-miR-630 consistently modulated mitochondrial/postmitochondrial steps of the intrinsic pathway of apoptosis, including Bax oligomerization, mitochondrial transmembrane potential dissipation, and the proteolytic maturation of caspase-9 and caspase-3. In addition, pre-miR-630 blocked early manifestations of the DNA damage response, including the phosphorylation of the ataxia-telangiectasia mutated (ATM) kinase and of two ATM substrates, histone H2AX and p53. Pharmacologic and genetic inhibition of p53 corroborated the hypothesis that pre-miR-630 (but not pre-miR-181a) blocks the upstream signaling pathways that are ignited by DNA damage and converge on p53 activation. Pre-miR-630 arrested A549 cells in the G0-G1 phase of the cell cycle, correlating with increased levels of the cell cycle inhibitor p27(Kip1) as well as with reduced proliferation rates and resulting in greatly diminished sensitivity of A549 cells to the late S-G2-M cell cycle arrest mediated by CDDP. Altogether, these results identify miR-181a and miR-630 as novel modulators of the CDDP response in NSCLC.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>20145152</pmid><doi>10.1158/0008-5472.can-09-3112</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 2010-03, Vol.70 (5), p.1793-1803
issn 0008-5472
1538-7445
language eng
recordid cdi_proquest_miscellaneous_733690564
source MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Antineoplastic agents
Antineoplastic Agents - pharmacology
Apoptosis - drug effects
Apoptosis - genetics
bcl-2-Associated X Protein - metabolism
Biological and medical sciences
Cadmium Chloride - pharmacology
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - metabolism
Carcinoma, Non-Small-Cell Lung - pathology
Caspases - metabolism
Cell Cycle - drug effects
Cell Cycle - genetics
Cell Line, Tumor
Cisplatin - pharmacology
DNA Damage
HeLa Cells
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - metabolism
Lung Neoplasms - pathology
Medical sciences
MicroRNAs - genetics
MicroRNAs - metabolism
MicroRNAs - physiology
Oligonucleotide Array Sequence Analysis - methods
Pharmacology. Drug treatments
Phosphorylation
Sphingosine - analogs & derivatives
Sphingosine - pharmacology
Tumor Suppressor Protein p53 - genetics
Tumor Suppressor Protein p53 - metabolism
Tumors
Up-Regulation - drug effects
title miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T03%3A14%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=miR-181a%20and%20miR-630%20Regulate%20Cisplatin-Induced%20Cancer%20Cell%20Death&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=GALLUZZI,%20Lorenzo&rft.date=2010-03-01&rft.volume=70&rft.issue=5&rft.spage=1793&rft.epage=1803&rft.pages=1793-1803&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/10.1158/0008-5472.can-09-3112&rft_dat=%3Cproquest_cross%3E733690564%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733690564&rft_id=info:pmid/20145152&rfr_iscdi=true